Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Stealth Biotherapeutics Corp ADR (MITO)

Stealth Biotherapeutics Corp ADR (MITO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Stealth BioTherapeutics Announces Mito Assist™ Patient Support Program and Specialty Pharmacy Partnership with AnovoRx to Distribute FORZINITY™(elamipretide) injection PR Newswire - Thu Oct 9, 8:30AM CDT

Program underscores Stealth's commitment to patient access and partnership with the Barth syndrome community

MITO : 0.3200 (-1.36%)
Stealth BioTherapeutics Corp Announces Completion of Merger PR Newswire - Wed Nov 16, 2022

/PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the...

MITO : 0.3200 (-1.36%)
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire - Tue Nov 1, 2022

/PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq : MITO), a clinical-stage biotechnology company focused on the discovery, development, and...

MITO : 0.3200 (-1.36%)
Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders PR Newswire - Fri Oct 7, 2022

/PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused on the discovery,...

MITO : 0.3200 (-1.36%)
Stealth BioTherapeutics Announces Departure of Chief Financial Officer PR Newswire - Fri Sep 30, 2022

/PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization...

MITO : 0.3200 (-1.36%)
Stealth BioTherapeutics to Participate in Upcoming Ultra-Rare Disease Events PR Newswire - Thu Sep 15, 2022

/PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development, and...

MITO : 0.3200 (-1.36%)
STEALTH BIOTHERAPEUTICS ANNOUNCES RECEIPT OF NON-COMPLIANCE NOTICE FROM NASDAQ PR Newswire - Mon Jul 11, 2022

/PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization...

MITO : 0.3200 (-1.36%)
Stealth BioTherapeutics Corp Announces Receipt of Preliminary Non-Binding Proposal PR Newswire - Mon Jun 27, 2022

/PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and...

MITO : 0.3200 (-1.36%)
Stealth BioTherapeutics Corp Announces Receipt of Preliminary Non-Binding Proposal PR Newswire - Mon Jun 27, 2022

/PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and...

MITO : 0.3200 (-1.36%)
Stealth BioTherapeutics Granted Pre-NDA Meeting for Elamipretide as a Potential Treatment for Barth Syndrome PR Newswire - Tue Jun 14, 2022

/PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization...

MITO : 0.3200 (-1.36%)

Barchart Exclusives

Mizuho Says This 1 Agentic AI Company Is the Top Software Stock to Buy in 2026 Barchart - 29 minutes ago
Despite a rocky year for Salesforce shares, Mizuho remains bullish on the stock, naming it a top software pick for 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot